India, March 13 -- The Government of India has issued a release:
The Department of Pharmaceuticals has received representations from the approved applicants under the Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as "PLI Scheme for Bulk Drugs") regarding the extension of scheme tenure. In this regard, the Government has decided not to give extension to the said scheme as it will result in an unfair benefit to non-performers and thereby, will be against the interest of those beneficiaries those have made efforts to meet the timelines.
i. India's dependence on imported A...